Navigation Links
Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium
Date:9/9/2011

.nektar.com/">http://www.nektar.com.

Forward-Looking StatementsThis press release contains forward-looking statements that reflect management's current views regarding NKTR-102 and certain other drug candidates in Nektar's pipeline.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delay, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; and (vi) certain other important risks and uncertainties set forth in Nektar's reports and other filings with the Sec
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. ... amended and increased its five-year revolving credit facility to ... an accordion feature that will allow the company to ... additional $30.0 million, subject to securing additional commitments from ... of the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... (PRWEB) April 25, 2015 The impact ... still eliciting the excitement of the public and is ... the months of May and June. From March ... their biannual tradition of "Special Prayers." More than 600 ... attended previous Special Prayers and have reported intense experiences ...
(Date:4/25/2015)... 25, 2015 Parker and Sons projects growth ... has spiked in Arizona alongside the growing economy. As a ... employees for April to help account for the rising need ... in April is something we are enthusiastic about. It means ... Kelly, president at Parker and Sons. , Indeed, Parker and ...
(Date:4/25/2015)... 2015 On Friday, April 17, Interstate ... annual Best Implementation Award. This award is given ... use of RFID technology to improve its manufacturing, supply ... that best demonstrates how RFID is delivering real value ... Journal Live! 2015 in San Diego, the RFID industries ...
(Date:4/24/2015)... April 24, 2015 Constellations Recovery celebrates ... in Westchester County. Just 35 miles from New York ... back into everyday life while recovering from addiction. The ... 2015, will allow therapists, doctors and treatment centers to ... more about the opportunities offered by Constellations Recovery.,  , ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Ryadon is ... wide range of capabilities and services to complement any ... Ryadon's Quantity Discount Program will be offered on all ... , Order 4-19: Receive 10% discount - Order 20+: ... Using the Drawer Slides Products, ...
Breaking Medicine News(10 mins):Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:Parker and Sons Plans to Expand in 2015 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3
... HealthDay Reporter , WEDNESDAY, June 15 (HealthDay News) -- ... leading nations in terms of life expectancy, and the gap ... Life expectancy in some areas of the United States is ... nations, the report found. "The gap between the U.S. ...
... Reporter , WEDNESDAY, June 15 (HealthDay News) -- Severely ... fade or become less frequent after having weight-reducing gastric ... the three years following surgery, 70 percent of the ... saw their migraines reduced from five to two a ...
... as nave and irrational, can actually help consumers cope ... to a new study in the Journal of ... an individual invokes mystical, supernatural forces to understand, predict, ... write authors Yannik St. James (HEC Montreal), Jay M. ...
... 2011, the New York Academy of Sciences will ... molecular biologists and patient advocates to discuss current ... and management of the cognitive symptoms of MS. ... Dysfunction in Multiple Sclerosis: New Approaches to Diagnosis ...
... -- A person scanning baggage or X-rays stands a ... they aren,t feeling anxious, according to a new laboratory ... a test in which they searched for particular shapes ... searching performed by airport security teams and radiologists. ...
... of asbestos-contaminated dust, have a higher level of genetic somatic ... lower. This has been shown in a new study carried ... the University of Haifa,s Department of Biology in Oranim. "This ... higher levels of asbestos in the environment and the frequency ...
Cached Medicine News:Health News:U.S. Found to Be Losing Ground in Life Expectancy 2Health News:U.S. Found to Be Losing Ground in Life Expectancy 3Health News:For Many, Weight-Loss Surgery Also Eases Migraines 2Health News:For Many, Weight-Loss Surgery Also Eases Migraines 3Health News:Magical thinking helps dieters cope with unrealistic expectations 2Health News:The New York Academy of Sciences to host a symposium on cognitive dysfunction in multiple sclerosis 2Health News:Anxious searchers miss multiple objects 2Health News:Genetic mutation linked to asbestos exposure 2
... provide protection to the exposed airway of the ... making it ideal for active young children as ... heat and moisture recovery, it ensures patient comfort ... filters have ISO standard tapered ends to assure ...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: